A Phase IV, Multicenter, Single-Arm, Open-Label Study to Assess the Efficacy and Safety of Tocilizumab in Chinese Patients With Systemic Juvenile Idiopathic Arthritis
Phase of Trial: Phase IV
Latest Information Update: 27 Feb 2018
At a glance
- Drugs Tocilizumab (Primary)
- Indications Juvenile rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Roche
- 05 Dec 2017 Status changed from not yet recruiting to recruiting.
- 17 Nov 2017 Planned initiation date changed from 20 Oct 2017 to 30 Nov 2017.
- 10 Oct 2017 New trial record